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Background: It is well known that percutaneous coronary intervention (PCI) in hemodialysis (HD) patients
is associated with higher rates of in-stent restenosis and major adverse cardiovascular events (MACE)
compared to that in non-HD patients, even if the target value in cholesterol management is achieved.
Methods: To evaluate the factors that are associated with MACE in HD patients, we selected 142 HD
patients (164 lesions) without acute coronary syndrome (ACS) from 2148 patients (2568 lesions) who
underwent PCI in our database of the FU-Registry [UMIN000005679, Fukuoka University Hospital EC/
IRB:10-1-08(09-105)], and compared 52 patients (53 lesions) with MACE [MACE(+)] to 90 patients (111
lesions) without MACE [MACE()].
Results: Total cholesterol (TC: 150  30 mg/dL vs 166  39 mg/dL, p < 0.05) and high-density lipoprotein
cholesterol (HDL-C: 40.1  14.7 mg/dL vs 47.8  13.5 mg/dL, p < 0.01) levels were signiﬁcantly lower in the
MACE(+) group at follow-up. No signiﬁcant differences were observed in other parameters, including
triglyceride, low-density lipoprotein cholesterol (LDL-C; LDL-C/HDL-C ratio, and % changes in HDL-C, non-
HDL-C, LDL-C), and hemoglobin A1c (US National Glycohemoglobin Standardization Program) between
before and after PCI. TC, LDL-C, and non-HDL-C at the time of PCI and TC, and HDL-C at the 9-month follow-up
were negatively correlated with MACE, while body mass index (BMI) [odds ratio (OR): 0.81; 95% conﬁdence
interval (CI): 0.68–0.95)], prior coronary artery bypass graft (CABG) (OR: 3.89; 95%CI: 1.29–12.6), and insulin
use (OR: 3.17; 95%CI: 1.23–8.55) were strongly correlated with MACE in a multivariate analysis.
Conclusion: BMI, CABG, and insulin use, but not LDL-C, are independent predictors of MACE in HD
patients, suggesting that the application of lipid management for non-HD patients to HD patients at the
time of PCI may not necessarily be beneﬁcial for medium-term clinical outcomes.
 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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(MACE) than that in non-HD patients, even if the target value in
cholesterol management is achieved [1,2]. A high level of low-
density lipoprotein cholesterol (LDL-C) is a major risk factor for
cardiovascular disease. However, in the AURORA trial [3], the LDL-
C level in HD patients was not higher than that in non-HD patients,
and the administration of statins in HD patients decreased LDL-C
levels with no reduction in cardiovascular risk.
HD patients have characteristics that are different from those of
non-HD patients. In HD patients, a decrease in lipoprotein lipase
activity causes an increase in both very-low-density lipoproteingy.
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triacylglycerol lipase (HTGL) level leading to an increase in
intermediate-density lipoprotein, resulting in a decrease in LDL-
C [4]. An increase in triglyceride (TG)-rich lipoprotein contributes
to the increased serum TG in HD patients [5–7]. HTGL also affects
the fractional catabolic rate of apolipoprotein (apo) A–I, the major
apolipoprotein of high-density lipoprotein (HDL), and an increase
in the catabolic rate of apo A–I results in a low HDL-cholesterol (C)
[8]. In addition, a decrease in lecithin-cholesterol acyltransferase
activity also causes a decrease in HDL-C [9,10].
Therefore, based on the hypothesis that there is a large
difference in the correlations between lipoprotein parameters
and the incidence of MACE in chronic HD and non-HD patients who
undergo PCI, we evaluated the factors that are related to MACE in
HD patients who underwent PCI by comparing patients who had
and did not have MACE at follow-up.
Methods
Patients
From 2148 patients (2568 lesions) who underwent PCI from
January 2003 to June 2012 at Fukuoka University Hospital,
Fukuoka University Chikushi Hospital, and Fukuoka White-Cross
Hospital (Hakujyuji Hospital), we selected 142 HD patients who
had stable angina pectoris and had undergone elective PCI (164
lesions), and divided them into a MACE() group (90 cases, 111
lesions) and a MACE(+) group (52 cases, 53 lesions) (Fig. 1). HD
patients with acute coronary syndrome (ACS) who underwent
emergent PCI were excluded. ACS included acute myocardial
infarction and unstable angina. Acute myocardial infarction was
diagnosed based on guidelines for the management of patients
with ST-elevation myocardial infarction (JCS 2008) [11]. Myocar-
dial infarction included both ST-elevation and non-ST-elevation
types, which exhibit either distinctive ischemic electrocardiogram
changes and/or elevated cardiac enzymes (creatine kinase more
than twice the reference value) [11]. We performed an angio-
graphical analysis using the database from the FU-Registry [12,13]
[UMIN000005679, Fukuoka University Hospital EC/IRB:10-1-
08(09-105)]. After an average of 286 days after PCI, all the patients
underwent a clinical follow-up to determine the presence of MACE
based on the ﬁndings at the last visit or a telephone call. Basically,
all the patients who underwent PCI should have been checked by
coronary angiography (CAG) after 9 months, which is the standard
procedure for medical care in Japan. However, some patients did
not receive CAG for various reasons and others were lost to follow-
up. Therefore, we interviewed these patients over telephone.
Angiographic follow-up was performed for 91.5% of all cases.Fig. 1. Outline of the study (the FU-Registry). ACS, acute coronary syndrome; MACE,
major adverse cardiovascular events.All-cause death, stent thrombus, myocardial infarction, and target
lesion revascularization (TLR) were deﬁned as MACE. TLR included
ischemia-driven TLR-PCI and TLR-cardiac artery bypass graft
(CABG), but did not include target lesion/vessel revascularization
(TVR) or non-TVR. Further, stent thrombosis was deﬁned to include
deﬁnite, probable, and possible types according to the ARC
(Academic Research Consortium) deﬁnition. If a patient had
multiple lesions and had undergone PCI in each vessel with
different devices at different times, the case number and event
number were different, since the background would be different.
However, if PCI was performed on multiple vessels at the same
time, the vessel that underwent intervention ﬁrst was considered
to be the vessel for analysis purposes. Therefore, in such a case, the
case number and event number should be the same.
Type 2 diabetes mellitus (DM) was deﬁned as fasting glucose
concentration 126 mg/dL, 2-h glucose 200 mg/dL in a 75 g oral
glucose tolerance test, or non-fasting glucose 200 mg/dL in two
separate blood tests. We also included patients who were receiving
the continued oral administration of hypoglycemic agents, or who
had evidently been diagnosed as having DM. Hypertension was
deﬁned as systolic blood pressure (SBP) 140 mmHg and/or
diastolic blood pressure (DBP) 90 mmHg. Dyslipidemia was
deﬁned as fasting levels of LDL-C 140 mg/dL, HDL-C <40 mg/dL,
or TG 150 mg/dL.
PCI intravascular ultrasound
PCI was performed in patients with more than 50% signiﬁcant
stenosis by angiography who also showed chest symptoms or
evidence of ischemia by a non-invasive test (treadmill electrocar-
diogram, myocardial scintigraphy). The endpoint for PCI was
determined to be the absence of any dissection that might obstruct
blood ﬂow to achieve thrombolysis in myocardial infarction (TIMI)
III ﬂow with 10% or less angiographic stenosis, which was
determined based on daily clinical practice. Intravascular ultra-
sound (IVUS) was used in 40% of the cases, since we used IVUS for
stent inﬂation and to assay the minimum lumen area, but data
were available in only 659 of 2568 lesions (25.7%). Since the results
of pre-procedural IVUS included many cases in which IVUS could
not be passed through lesions, these cases were not included in the
present analysis and only the results of post-procedural IVUS were
used.
Medication (antiplatelets)
With regard to the use of antiplatelets, the administration  of
aspirin (100 mg) and 200 mg of ticlopidine or 75 mg of clopidogrel
was started in all cases at least 48 h before stent insertion. In principle,
antiplatelets other than aspirin were administered continuously for at
least 2 weeks in patients with a bare metal stent and all antiplatelets
were administered for at least nine months after PCI in patients with
an indwelling drug-eluting stent (DES).
Quantitative coronary angiography
Quantitative coronary angiography (QCA) was performed in
1,775 of 2,568 lesions (69.1%). QCA data were not available for all of
the lesions because (1) follow-up CAG was not performed both in
our hospital and two other collaborating hospitals, or (2) lesions for
QCA analyses were randomly selected during the period when we
started to establish a QCA analysis system (between 2003 and
2005). Quantitative and qualitative analyses were performed using
CMS-GFT (MEDES, Amsterdam, The Netherlands) at Fukuoka
University, which was the core laboratory for the study, as
described previously [13–17]. An analysis was performed for
angiograms obtained at pre-procedural and post-procedural
Table 1
Patient characteristics and results of blood tests at PCI procedure and follow-up.
MACE() (n = 90) MACE(+) (n = 52)
Clinical characteristics at PCI procedure
Mean age (years) 69.5  8.7 68.5  7.4
BMI (kg/m2) 21.5  3.8 20.3  2.3*
Male (%) 70.0 75.0
SBP (mmHg) 137.6  23.8 138.5  26.4
DBP (mmHg) 70.4  13.9 68.7  13.0
Pulse rate (/min) 75.9  11.6 78.4  11.4
UCG-LVEF (%) 58.6 53.0*
Clinical characteristics at follow-up
BMI (kg/m2) 21.1  3.2 20.0  1.8*
BMI percent change (%) 0.97 0.67
LVEF-UCG (%) 56.8 52.6
Blood tests at PCI procedure
ALB (mg/dL) 3.9  0.5 3.8  1.0
UA (mg/dL) 6.1  1.7 5.3  1.8y
TC (mg/dL) 173  44 158  34*
TG (mg/dL) 121  66 122  82
HDL-C (mg/dL) 45.4  13.3 43.1  12.3
Non-HDL-C (mg/dL) 128  41 116  33
LDL-C (mg/dL) 104  36 90  25*
LDL-C/HDL-C 2.5  1.0 2.3  0.8
HbA1c (%) 6.0 5.9
Blood tests at follow-up
ALB (mg/dL) 3.5  0.2 3.1  0.3
TC (mg/dL) 166  39 150  30*
TG (mg/dL) 117  60 127  70
HDL-C (mg/dL) 47.8  13.5 40.1  14.7y
LDL-C (mg/dL) 94  33 84  26
LDL-C/HDL-C 2.14 2.43
Non-HDL-C (mg/dL) 117  37 110  27
LDL-C percent change (%) 4.9 6.9
HDL-C percent change (%) 9.4 1.5
Non-HDL-C percent change (%) 1.3 2.9
HbA1c (%) 6.0  1.2 6.2  1.1
Prior complicating diseases
Prior PCI (%) 54.4 71.2
Prior CABG (%) 8.9 28.8y
Prior MI (%) 23.3 46.2y
ASO (%) 24.4 25.0
Hypertension (%) 82.2 80.8
Hyperlipidemia (%) 44.4 40.4
Type 2 diabetes (%) 62.2 75.0
NSGP value was presented for HbA1c.
MACE: major adverse cardiovascular events; BMI: body mass index; SBP:
systolic blood pressure; DBP: diastolic blood pressure; UCG LVEF: ultrasound
cardiography left ventricle ejection fraction; ALB: albumin; UA: uric acid; TC:
total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein-cholesterol;
non-HDL-C: non-high density lipoprotein-cholesterol; LDL-C: low-density lipopro-
tein-cholesterol; L/H ratio: LDL-C/HDL-C; HbA1c: hemoglobin A1c; PCI: percutane-
ous coronary intervention; CABG: coronary artery bypass graft; MI: myocardial
infarction; ASO: arteriosclerosis obliterans; TC percent change = {TC (follow-
up)  TC (pre)}/TC (pre)  100; LDL-C percent decrease = {LDL-C (follow-up) 
LDL-C (pre)}/LDL-C (pre)  100; HDL-C percent increase = {HDL-C (follow-up) 
HDL-C (pre)}/HDL-C (pre)  100; non-HDL-C percent decrease = {non-HDL-C
(pre) non-HDL-C (follow-up}/non-HDL-C (pre)  100.
* p < 0.05.
y p < 0.01.
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phy after the intracoronary injection of nitroglycerin. Segments
were deﬁned as the in-stent region, the proximal edge of the stent,
and a region 5.0 mm from the distal edge, respectively. A late loss
was deﬁned as the difference in the minimum lesion diameter
between the post-procedural angiogram and the follow-up
angiogram. In addition, restenosis was deﬁned as a stenosis rate
of 50% or higher, as described previously [13].
Statistical data analysis
We collected the data in a Filemaker Pro database and then
exported into an Excel spreadsheet for analysis. Statistical data
analysis was performed using SAS software (Version 9.1 SAS
Institute, Cary, NC, USA) at Fukuoka University. The chi-square test
was used to compare categorical variables between groups. The
Wilcoxon rank-sum test and Student t-test were used to compare
continuous variables between groups, which were expressed as
the mean  SD. Correlations between variables were examined by
the Spearman correlation. The associations between the predictor
variables at the time of PCI with MACE were examined by a simple
logistic regression analysis. The independence of the associations
among the predictor variables at the time of PCI that were associated
with MACE was examined by a multiple logistic regression analysis,
and variables included in the model were selected using the Score
selection method [18]. The multicollinearity of explanatory variables
was diagnosed using a regression analysis [19]. A value of p < 0.05
was considered to reﬂect statistical signiﬁcance.
Results
With regard to the patient background, the MACE(+) group
showed signiﬁcantly lower percentages of ultrasound cardiography-
LVEF (53.0% vs 58.6%, p = 0.02) and lower levels of TC (158  34 mg/
dL vs 173  44 mg/dL, p = 0.03), LDL-C (90  25 mg/dL vs 104 
36 mg/dL, p = 0.01), and uric acid (5.3  1.8 mg/dL vs 6.1  1.7 mg/dL,
p = 0.07) at the PCI procedure, compared to the MACE() group (Table 1).
Although no difference in albumin was observed between the groups,
BMI was signiﬁcantly lower (20.3  2.3 kg/m2 vs 21.5  3.8 kg/m2,
p = 0.02) in the MACE(+) group. With regard to prior/complicating
disease, the MACE(+) group had signiﬁcantly (p < 0.01) higher
percentages of prior MI and prior CABG.
While BMI at the time of PCI follow-up (after an average of 286
days) was also signiﬁcantly lower (20.0  1.8 kg/m2 vs 21.1 
3.2 kg/m2, p = 0.01) in the MACE(+) group, there were no signiﬁcant
differences in the percent reduction in BMI. At the follow-up, TC
(150  30 mg/dL vs 166  39 mg/dL, p = 0.02) and HDL-C (40.1 
14.7 mg/dL vs 47.8  13.5 mg/dL, p = 0.01) in the MACE(+) group
were signiﬁcantly lower than those in the MACE() group. No
signiﬁcant differences were observed in other parameters, including
TG, LDL-C, L/H ratio, or % changes in HDL-C, non-HDL-C, LDL-C, or
HbA1c (Table 1).
At the time of PCI, there was no difference in the % use of
antihypertensive drugs or statin drugs, or in the percentage of
patients with DM between the groups, while the MACE(+) group
showed a signiﬁcantly higher percentage of insulin use (44.2% vs
24.4%, p = 0.02). The MACE(+) group also showed signiﬁcantly higher
use rates for nitrates and insulin at the time of follow-up (Table 2).
As shown in Table 3, among the lesion characteristics, while
there was no signiﬁcant difference in the percentage of extensive
calciﬁcation, the MACE(+) group showed signiﬁcantly higher
percentages of pre-in-stent restenosis (49.1% vs 31.5%, p < 0.05)
and left main trunk lesions (26.4% vs 4.5%, p < 0.001), and a
tendency for a lower rate of use of DES (47.2% vs 64.9%, p = 0.10).
The results of pre- and post-procedural QCA and IVUS were similar
in the two groups (Table 3). With regard to the clinical outcome,the frequencies of MACE, i.e. TLR-PCI, death, stent thrombus, MI,
and TLR-CABG, were 80.8%, 15.4%, 13.5%, 9.6%, and 3.9%,
respectively (Table 4).
In a univariate analysis of the relations between lipoprotein
parameters and MACE, negative relations were seen among MACE
and TC, LDL-C, and non-HDL-C at the time of PCI, as well as TC and
HDL-C at the time of follow-up. The independence of the association
among the predictor variables at the time of PCI that were associated
with MACE was examined by a multiple logistic regression analysis
with the following models – Model 1: single LDL-C; Model 2: single
LDL-C + BMI; Model 3: single LDL-C + prior CABG; Model 4: single
LDL-C + insulin use; Model 5: single LDL-C + BMI + prior CABG
Table 2
Medications at PCI procedure and follow-up.
MACE() (n = 90) MACE(+) (n = 52)
Medications at PCI procedure
Ca blocker (%) 51.1 50.0
ACEI (%) 11.2 7.7
B-blocker (%) 13.3 17.3
Statin (%) 26.7 36.5
Nitrate (%) 40.0 36.5
ARB (%) 41.1 50.0
Nicorandil (%) 40.0 36.5
Insulin (%) 24.4 44.2*
DPP-4 inhibitor (%) 2.2 0
Medications at follow-up
Ca blocker (%) 44.4 55.8
ACEI (%) 6.7 11.6
B-blocker (%) 14.4 19.2
Statin (%) 38.9 38.5
Nitrate (%) 33.3 57.7y
ARB (%) 43.3 48.1
Nicorandil (%) 27.8 42.3
Insulin (%) 24.4 46.2*
DPP-4 inhibitor (%) 1.1 0
MACE: major adverse cardiovascular events; ACEI: angiotensin converting
enzyme inhibitor; ARB: angiotensin receptor blocker; DPP-4 inhibitor:
dipeptidyl peptidase-4 inhibitor.
* p < 0.05.
y p < 0.01.
Table 4
Lesion characteristics, follow-up QCA results, and clinical outcomes.
MACE() MACE(+)
n = 97 n = 53
Angiographic follow-up results
In-stent restenosis (%) 9.3 90.6z
N = 40 N = 21
Follow-up QCA
Lesion late loss (mm) 0.20  0.61 0.95  0.87
Lesion %DS (%) 28.5 71.0
n = 90 n = 52
Clinical outcomes (MACE)
Stent thrombus (%) 0 13.5
Death (%) 0 15.4
MI (%) 0 9.6
TLR-PCI (%) 0 80.8
TLR-CABG (%) 0 3.9
MACE: major adverse cardiovascular events; MI: myocardial infarction; TLR-
PCI: target lesion restenosis-percutaneous coronary intervention; TLR-CABG:
target lesion restenosis-cardiac artery bypass graft.
*p < 0.05.
yp < 0.01.
zp < 0.001.
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0.95)], prior CABG [OR: 3.89 (95%CI: 1.29–12.6)] and insulin [OR:
3.17 (95%CI: 1.23–8.55)] were independently associated with MACE
(Table 5). LDL-C was not signiﬁcantly associated with MACE after
adjusting for BMI, prior CABG, and insulin in HD patients.Table 3
Lesion characteristics and pre- and post-procedural QCA results.
MACE() MACE(+)
n = 111 n = 53
Lesion characteristics
3-vessel disease (%) 50.4 58.5
RCA/LAD/Cx (%) 35.1/42.3/22.6 35.7/45.2/19.1
Pre-in-stent restenosis (%) 31.5 49.1*
AHA/ACC type B2+C (%) 72.9 77.4
Severe calciﬁcation (%) 36.0 47.2
DES (%) 64.9 47.2
LMT (%) 4.5 26.4y
n = 56 n = 30
Pre-procedural QCA results
Lesion length (mm) 17.4  9.7 19.3  15.9
Angulation (%) 28.8 31.7
Reference (mm) 2.7  0.8 2.5  0.6
MLD (mm) 0.7  0.5 0.7  0.3
%DS (%) 70.4 71.6
n = 56 n = 30
Post-procedural QCA results
Reference (mm) 2.6  0.6 2.6  0.6
MLD (mm) 2.0  0.6 2.0  0.6
%DS (%) 28.1 24.8
Stent length (mm) 24.3  13.1 21.5  13.7
Stent reference (mm) 2.9  0.5 2.8  0.5
Stent MLD (mm) 2.5  0.5 2.4  0.5
Stent %DS (%) 14.9 12.1
MACE: major adverse cardiovascular events; RCA: right coronary artery; LAD:
left anterior descending; Cx: left circumﬂex branch; MLD: minimum lumen
diameter; %DS: percent diameter stenosis; IVUS: intravascular ultrasound; CSA:
cross-sectional area; EEM: external elastic membrane.
* p < 0.05.
y p < 0.01.Discussion
It is well known that medium- and long-term clinical outcomes
can be affected by an abnormal lipid metabolism in the primary
and secondary prevention of coronary artery disease. However, in
the AURORA trial [3], in which 2776 HD patients were divided into
a placebo group and a treatment group that received rosuvastatin
at 10 mg/day, the combined endpoint of events such as cardiovas-
cular death, non-fatal MI, and non-fatal cerebral vascular disorder
was not signiﬁcantly reduced in the treatment group, with a
decrease of only 4%. In addition, in 2005, the 4D study, in which
1255 HD patients with DM were randomly assigned to receive
either 20 mg of atorvastatin per day or matching placebo, did not
show a signiﬁcant reduction in the primary endpoint [20]. The
SHARP trial was conducted in 9720 patients with chronic kidney
disease (CKD) with no known history of cardiovascular disease, and
33% of the patients were on HD [21]. Patients were assigned to
receive either simvastatin 20 mg plus ezetimibe 10 mg daily or
placebo with a median follow-up of 4.9 years. This combination
therapy reduced the incidence of major atherosclerotic events in a
wide range of patients with CKD. After the researchers adjusted for
the reduction in LDL-C, the proportional reductions in major
atherosclerotic events per 1 mmol/L reduction in LDL-C were
similar for stage 4 and 5 CKD patients; however, the subgroup of
patients with dialysis showed no signiﬁcant beneﬁt with
treatment [21]. These ﬁndings suggest that we should not expect
to see an overall decrease in the risk of cardiovascular disease for
patients who are receiving HD therapy under lipid-lowering
therapy based on statins.
Very few registry studies or non-statin trials have investigated
the factors that are related to MACE in HD patients who underwent
PCI. In the present study, we divided stable angina patients who
were receiving maintenance HD into two groups according to the
presence or absence of MACE, and examined the relation between
the LDL-C level and MACE. Although the MACE(+) group showed a
signiﬁcantly lower LDL-C level at PCI (Table 1), the LDL-C level was
not independently associated with MACE in a multivariate
analysis. Further, an examination of the correlation between
statin use and MACE showed an OR of 1.27 (95%CI: 0.54–2.9) (data
not shown), and thus we could not conﬁrm the effectiveness of
Table 5
Multivariate logistic regression analysis of the independent predicting factor for MACE in HD patients.
Odds ratio (95% conﬁdence Intervals)
Model 1 Model 2 Model 3 Model 4 Model 5
LDL-C 0.99 (0.97–1.00)* 0.99 (0.97–1.00) 0.99 (0.98–1.00) 0.99 (0.97–1.00) 0.99 (0.98–1.01)
BMI 0.88 (0.76–1.01) 0.81 (0.68–0.95)*
Prior CABG 3.13 (1.15–8.96)* 3.89 (1.29–12.6)*
Insulin 2.40 (1.03–5.59)* 3.17 (1.23–8.55)*
Model 1: single LDL-C (at the time of PCI).
Model 2: LDL-C (at the time of PCI) + BMI (at the time of PCI).
Model 3: LDL-C (at the time of PCI) + Prior CABG (at the time of PCI).
Model 4: LDL-C (at the time of PCI) + Insulin (at the time of PCI).
Model 5: LDL-C (at the time of PCI) + BMI (at the time of PCI) + Prior CABG (at the time of PCI) + Insulin use (at the time of PCI).
MACE: major adverse cardiovascular events, CABG: coronary artery bypass graft, BMI: body mass index, LDL-C: Low density lipoprotein-cholesterol.
* p < 0.05.
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trials.
Since LDL-C is generally an important risk factor for MACE, as
shown in the MEGA [22], MEGA-CKD [23], and other studies [24],
we compared the associations between lipoprotein parametersFig. 2. (A) The associations between lipid and lipoprotein parameters and the incidence 
presented as odds ratio (95% conﬁdence interval). *p < 0.05, assessed by logistic regressio
stratiﬁed into ﬁve groups (LDL-C < 80 mg/dL, 80–100 mg/dL, 100–120 mg/dL, 120–140 m
stable angina. Data are presented as odds ratio (95% conﬁdence interval). *p < 0.05, asse
total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; HD, heand the incidence of MACE in 1578 non-HD patients with stable
angina (number of lesions: 1,909, pre-LDL-C: 106  48 mg/dL, post-
LDL-C: 93  29 mg/dL) to the results in 142 HD patients in our FU-
Registry analysis (Fig. 2A). The results showed that the LDL-C level, TC,
and non-HDL-C were signiﬁcantly associated with MACE (Fig. 2A), butof MACE in 1578 non-HD patients and 142 HD patients with stable angina. Data are
n analysis. (B) The association between LDL-C and the incidence of MACE. LDL-C was
g/dL, and 140 mg/dL < LDL-C) in 1578 non-HD patients and 142 HD patients with
ssed by logistic regression analysis. LDL-C, low-density lipoprotein cholesterol; TC,
modialysis.
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HD patients. We stratiﬁed the patients into ﬁve groups according to
the LDL-C level (LDL-C < 80 mg/dL, 80–100 mg/dL, 100–120 mg/dL,
120–140 mg/dL, and >140 mg/dL), and the relation between LDL-C
and the incidence of MACE was investigated in each group (Fig. 2B).
The results showed that the LDL-C-associated risk of MACE increased
as the LDL-C level increased in the non-HD group, and was negative in
patients with LDL-C < 80 mg/dL and positive in patients with LDL-C
120–140 mg/dL and 140 mg/dL. In contrast to non-HD patients, we
found that the risk of MACE tended to decrease with an increase in the
LDL-C value in HD patients, and was negative in patients with LDL-
C > 140 mg/dL. Even though our study focused on the outcome of PCI
with/without HD, and our registry is not a cholesterol-lowering
intervention, we can at least conclude that lipid management in HD
patients with PCI should be different from that in non-HD patients if
we also consider the data from previous studies.
Ikewaki et al. [25] reported that LDL and LDL-apoB remain in the
blood almost twice as long in HD patients as in normal subjects due
to a reduced catabolic rate of apo B, such as that associated with a
reduction in LDL being taken up into the liver. Therefore, LDL in HD
patients is prone to be modiﬁed by oxidation or denaturation in
blood vessels, which suggests that large amounts of such modiﬁed
LDL circulate in the blood of HD patients. While we previously
reported that fast-migrating (modiﬁed or electronegative) LDL
[26–28] was increased in HD patients, plasma TC and slow-
migrating (not modiﬁed or electropositive) LDL fractions were
within the normal range in such patients. In addition, it has also
been reported that the amount of time that LDL remains in the
blood is extended in CKD as the disease progresses [29]. An in vitro
experiment suggested that regulation of the pro-apoptotic protein
BAD by uremic toxins may increase cardiovascular toxicity [30].
Thus, such patients under maintenance HD are in a uremic state
and the duration of exposure to uremia is directly related to the
duration of HD. Lowering of the serum LDL-C level may not
adequately reduce the risk, and current target values in lipid
management may not be useful for preventing MACE in HD. More
comprehensive management schemes that do not involve statin/
lipid control but rather seek to lower BMI or insulin use, or prior
PCI, based on our ﬁndings in a multivariate analysis, should be the
focus for HD patients with PCI [31].
It has also been reported that, in systemic erythematosus,
chronic inﬂammation (high C-reactive proteinemia) is associated
with the development of new cardiovascular disease [32], and C-
reactive protein levels predict restenosis and MACE after PCI in
both non-dialysis patients [33,34] and HD patients [35].
Therefore, increased inﬂammatory cytokine levels caused by
maintenance HD may induce neointimal proliferation at sites
where PCI was performed, which could promote MACE. The
changes in lipoprotein parameters including LDL-C, HDL-C, non-
HDL-C, etc., might just be secondary factors caused by the chronic
inﬂammation.
Our study has some limitations. Since the present study is a
retrospective analysis of patients who underwent PCI from January
2003 to June 2012, the results may need to be further supported by
prospective analyses. Since the total number of HD patients was
142, changes in long-term clinical outcomes may also need to be
conﬁrmed by increasing both the total number of patients and the
duration of follow-up. Factors such as HD duration, hemoglobin
levels, Ca, P and so on greatly affect adverse events in the dialysis
population. In our FU-Registry, while we did not include such
parameters, we did consider albumin, and no difference in albumin
levels was observed between the MACE(+) and MACE() groups
(Table 1). We did not examine the effects of different types of DES,
which were used in our registry during 2003–2012, on MACE in HD
patients. Even if a DES including sirolimus- or paclitaxel-eluting
stents or recent second-generation stents is used, deﬁnite evidencethat DES reduce MACE in HD patients may not be anticipated, as
reported [36–38].
In conclusion, BMI, prior CABG, and insulin use, but not LDL-C,
are independent predictors of MACE in HD patients, suggesting
that the application of lipid management for non-HD patients to
HD patients at the time of PCI may not necessarily be beneﬁcial for
medium-term clinical outcomes.
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